Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy

There have been few reports on 2 tumor necrosis factor alpha inhibitors, infliximab and adalimumab, with respect to patient preference and efficacy in ulcerative colitis (UC). We used questionnaires to evaluate the preference and reasons for drug choice between infliximab and adalimumab in UC patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizoshita, Tsutomu, Katano, Takahito, Tanida, Satoshi, Hirano, Atsuyuki, Miyaki, Tomokatsu, Ozeki, Keiji, Suzuki, Yuka, Sugimura, Naomi, Kataoka, Hiromi, Joh, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
4500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5556246/
https://www.ncbi.nlm.nih.gov/pubmed/28796080
http://dx.doi.org/10.1097/MD.0000000000007800

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5556246/
https://www.ncbi.nlm.nih.gov/pubmed/28796080
http://dx.doi.org/10.1097/MD.0000000000007800

Ejemplares similares